Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0BIQJZ
ADC Name	Anti-BCMA L15-SG3249
Synonyms	Anti-BCMA-L15 SG3249 Click to Show/Hide
Organization	MedImmune LLC
Drug Status	Investigative
Indication	In total 2 Indication(s) Multiple myeloma [ICD11:2A83] Investigative Plasma cell myeloma [ICD11: 2A83] Investigative
Drug-to-Antibody Ratio	1.8
	3D MOL	2D MOL
Antibody Name	Anti-BCMA antibody L15		Antibody Info
Antigen Name	Tumor necrosis factor receptor superfamily member 17 (TNFRSF17)		Antigen Info
Payload Name	SG3199		Payload Info
Therapeutic Target	Human Deoxyribonucleic acid (hDNA)		Target Info
Linker Name	CL2A		Linker Info
Conjugate Type	Random conjugation through reduced inter-chain cysteines.
Combination Type	SG3249

General Information of The Activity Data Related to This ADC

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 3 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Tumor Growth Inhibition value (TGI)	≈ 95.16	%	CVCL_2078	Plasma cell myeloma
Tumor Growth Inhibition value (TGI)	≈ 96.37	%	CVCL_8792	Plasma cell myeloma
Tumor Growth Inhibition value (TGI)	≈ 97.35	%	CVCL_1600	Plasma cell myeloma

Full List of Activity Data of This Antibody-drug Conjugate

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 3 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 95.16% (Day 21)	Moderate BCMA expression (BCMA++)
Method Description	Mice were treated with either a single intravenous dose of ADCs at 1 mg/kg, or dosed intravenously with J6M0-mc-MMAF ADC weekly at a dose of 1 mg/kg for 3 weeks. Control mice were left untreated.
In Vivo Model	JJN-3 CDX model
In Vitro Model	Plasma cell myeloma	JJN-3 cells		CVCL_2078
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 96.37% (Day 32)	Moderate BCMA expression (BCMA++)
Method Description	Mice were treated with either a single intravenous dose of ADCs at 1 mg/kg, or dosed intravenously with J6M0-mc-MMAF ADC weekly at a dose of 1 mg/kg for 4 weeks. Control mice were left untreated.
In Vivo Model	MM.1S CDX model
In Vitro Model	Plasma cell myeloma	MM1.S cells		CVCL_8792
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 97.35% (Day 21)	High BCMA expression (BCMA+++)
Method Description	Mice were treated with either a single intravenous dose of the ADCs at 0.3 mg/kg or dosed intravenously with J6M0-mc-MMAFweekly at a dose of 0.3 mg/kg for 2 weeks.
In Vivo Model	NCI-H929 CDX model
In Vitro Model	Plasma cell myeloma	NCI-H929 cells		CVCL_1600

References

Ref 1	Bcma monoclonal antibody-drug conjugate.